Storied Nuclear Manufacturer, Niagara Energy Products, joins the CNIC

TORONTO – August 24, 2021 – Niagara Energy Products (NEP), a leader in the field of manufacturing radiation shielded containment vessels for isotopes and nuclear contaminated waste, has joined the Canadian Nuclear Isotope Council (CNIC). NEP has a long and storied history in Canada, with three large manufacturing plants in Ontario, providing high-quality jobs in … Read more

New partnership advances medical isotope technology

McMaster University and Promation have signed a Memorandum of Understanding (MoU) to work together to bring a new medical isotope technology developed at McMaster to the marketplace. At the center of this collaboration is a new technology for producing lutetium-177 (Lu-177), an increasingly sought-after medical isotope. Clinical trials have shown that Lu-177-based drugs have tremendous … Read more

CNIC signs historic MOU to collaborate on the 11th International Conference on Isotopes

TORONTO – May 12 , 2021  –The Canadian Nuclear Isotope Council (CNIC)  and the Local Organizing Committee of the 11th International Conference on Isotopes (11ICI) have entered into a Memorandum of Understanding to co-promote and support the conference’s success in 2022. The 11ICI will be  hosted by Sylvia Fedoruk Canadian Centre for Nuclear Innovation in … Read more

BWXT Medical Enters into a New Long-Term Agreement with Boston Scientific

(Ottawa, Ontario – May 10, 2021) – BWXT Medical Ltd. (BWXT Medical) announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company. Developed for the treatment of patients with hepatocellular carcinoma (HCC), TheraSphere treatment is comprised of millions … Read more

New report shines spotlight on Canadian isotope excellence

Medical isotope ecosystem directory details tremendous capabilities of Canada’s isotope industry.   Today, the Organization of Canadian Nuclear Industries (OCNI) and the Canadian Nuclear Isotope Council (CNIC) released the Canadian Medical Isotope Ecosystem Directory. The directory demonstrates the capabilities of the Canadian isotope sector companies and their leading international expertise as well as highlights the … Read more

Canada is an Isotope Superpower

On the CNIC’s 3rd birthday we highlight why the isotope sector is key contributor to economic recovery. The importance of nuclear medicine and medical isotopes in our daily lives — and Canada’s global leadership position in this sector — admittedly flies under the radar for most people, and their significance has never been more vital … Read more

Storied Canadian manufacturer, Advanced Cyclotron Systems, joins the CNIC

TORONTO – March 31, 2021 – Advanced Cyclotron Systems Inc. (ACSI), a world leader in the design and manufacturing of cyclotron equipment, including PET and SPECT radioisotope production cyclotrons, will join the Canadian Nuclear Isotope Council (CNIC), further cementing the industry association as the pre-eminent representative of the Canadian Isotope sector. “Over the past two-and-half … Read more

CNIC and Bangor University partner to export Canadian isotope sector expertise following digital trade mission

TORONTO – March 30, 2021 – Following a market study completed in March 2020, the Welsh government worked with the Organization of Canadian Nuclear Industries, the Canadian Nuclear Association, and Natural Resources Canada on a digital trade mission. The four-day event explored bilateral opportunities in Canada, the UK, and other markets of interest for Welsh … Read more

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that … Read more